A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease

Thrombosis Research

Volumn 132, Issue 3, 2013, Pages 341-345

  Desai, Payal C ^a,c   Brittain, Julia E ^a,d   Jones, Susan K ^a   McDonald, Adam ^a   Wilson, Douglas R ^b   Dominik, Rosalie ^b   Key, Nigel S ^a   Parise, Leslie V ^a   Ataga, Kenneth I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Acute painful episode; Eptifibatide; Platelet activation; Safety; Sickle cell disease

Indexed keywords

EPTIFIBATIDE; OPIATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HOSPITAL DISCHARGE; HUMAN; MALE; NAUSEA; PAIN; PATHOPHYSIOLOGY; PATIENT CONTROLLED ANALGESIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SICKLE CELL PAIN CRISIS; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOCYTOSIS;

ACUTE PAINFUL EPISODE; CD40 LIGAND; CD40L; CI; CONFIDENCE INTERVALS; EPTIFIBATIDE; PATIENT CONTROLLED ANALGESIA; PCA; PLATELET ACTIVATION; SAFETY; SCD; SICKLE CELL DISEASE;

ACUTE PAIN; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883807945     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.08.002     Document Type: Article

References (45)

1. R. Francis Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion Blood Coagul Fibrinolysis 2 2 1991 341 353
2. D.P. Inwald, F.J. Kirkham, M.J. Peters, R. Lane, A. Wade, and J.P. Evans Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia Br J Haematol 111 2 2000 474 481
3. J. Villagra, S. Shiva, L.A. Hunter, R.F. Machado, M.T. Gladwin, and G.J. Kato Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin Blood 110 6 2007 2166 2172
4. T. Wun, T. Paglieroni, F. Tablin, J. Welborn, K. Nelson, and A. Cheung Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia J Lab Clin Med 129 5 1997 507 516
5. A. Tomer, L.A. Harker, S. Kasey, and J.R. Eckman Thrombogenesis in sickle cell disease J Lab Clin Med 137 6 2001 398 407
6. S.P. Lee, K.I. Ataga, E.P. Orringer, D.R. Phillips, and L.V. Parise Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia Potential Role for Platelet-Mediated Inflammation Arterioscler Thromb Vasc Biol 26 7 2006 1626 1631
7. K.I. Ataga, J.E. Brittain, P. Desai, R. May, S. Jones, and J. Delaney Association of coagulation activation with clinical complications in sickle cell disease PLoS One 7 1 2012 e29786
8. U. Schonbeck, F. Mach, and P. Libby CD154 (CD40 ligand) Int J Biochem Cell Biol 32 7 2000 687 693 [Epub 2000/06/17]
9. U. Schonbeck, and P. Libby The CD40/CD154 receptor/ligand dyad Cell Mol Life Sci 58 1 2001 4 43 [Epub 2001/03/07]
10. C. Van Kooten, and J. Banchereau CD40-CD40 ligand: a multifunctional receptor-ligand pair Adv Immunol 61 1996 1 77 [Epub 1996/01/01]
11. C. van Kooten, and J. Banchereau CD40-CD40 ligand J Leukoc Biol 67 1 2000 2 17 [Epub 2000/01/27]
12. V. Henn, J.R. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster, and G. Muller-Berghaus CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 6667 1998 591 594 [Epub 1998/02/19]
13. M.I. Furman, L.A. Krueger, M.D. Linden, M.R. Barnard, A.L. Frelinger III, and A.D. Michelson Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization J Am Coll Cardiol 43 12 2004 2319 2325 [Epub 2004/06/15]
14. M.P. Curran, and G.M. Keating Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention Drugs 65 14 2005 2009 2035 [Epub 2005/09/16]
15. M.B. Holmes, B.E. Sobel, and D.J. Schneider Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects Am J Cardiol 84 2 1999 203 207 [Epub 1999/07/30]
16. M. Moser, U. Bertram, K. Peter, C. Bode, and J. Ruef Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates J Cardiovasc Pharmacol 41 4 2003 586 592 [Epub 2003/03/27]
17. L. Nannizzi-Alaimo, V.L. Alves, and D.R. Phillips Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation Circulation 107 8 2003 1123 1128 [Epub 2003/03/05]
18. F.G. Welt, S.D. Rogers, X. Zhang, R. Ehlers, Z. Chen, and L. Nannizzi-Alaimo GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention Catheter Cardiovasc Interv 61 2 2004 185 189 [Epub 2004/02/03]
19. A. Aggarwal, D.J. Schneider, E.F. Terrien, C.M. Terrien Jr., B.E. Sobel, and H.L. Dauerman Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting Am J Cardiol 91 11 2003 1346 1349 [Epub 2003/05/28]
20. M. Lele, M. Sajid, N. Wajih, and G.A. Stouffer Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin Circulation 104 5 2001 582 587 [Epub 2001/08/02]
21. T. Heitzer, I. Ollmann, K. Koke, T. Meinertz, and T. Munzel Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease Circulation 108 5 2003 536 541 [Epub 2003/07/23]
22. S.P. Lee, K.I. Ataga, M. Zayed, J.M. Manganello, E.P. Orringer, and D.R. Phillips Phase I study of eptifibatide in patients with sickle cell anaemia Br J Haematol 139 4 2007 612 620
23. R.G. Newcombe Interval estimation for the difference between independent proportions: comparison of eleven methods Stat Med 17 8 1998 873 890
24. M. Stokes, and G. Koch Up To Speed With Categorical Data Analysis 2011
25. J. Hodges Jr. Hodges-Lehmann Estimators Encyclopedia of Statistical Sciences 3 1983 642 645
26. D.C. Brousseau, J.P. Scott, C.A. Hillery, and J.A. Panepinto The effect of magnesium on length of stay for pediatric sickle cell pain crisis Acad Emerg Med 11 9 2008 968 972
27. M.T. Gladwin, G.J. Kato, D. Weiner, O.C. Onyekwere, C. Dampier, and L. Hsu Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis A Randomized Controlled Trial JAMA 305 9 2011 893 902
28. T.C. Griffin, D. McIntire, and G.R. Buchanan High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease N Eng J Med 330 11 1994 733 737
29. E.P. Orringer, J.F. Casella, K.I. Ataga, M. Koshy, P. Adams-Graves, and L. Luchtman-Jones Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease JAMA 286 17 2001 2099 2106
30. M.H. Qari, S.K. Aljaouni, M.S. Alardawi, H. Fatani, F.M. Alsayes, and P. Zografos Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial Thromb Haemost 98 2 2007 392
31. D.L. Weiner, P.L. Hibberd, P. Betit, A.B. Cooper, C.A. Botelho, and C. Brugnara Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease JAMA 289 9 2003 1136 1142
32. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 9247 2000 2037 2044
33. S. Attaya, Y. Kanthi, R. Aster, and K. McCrae Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction Platelets 20 1 2009 64 67
34. M. Tahir, A. Banday, S. Karim, and P.R. Sullivan Acute Profound Thrombocytopenia Following Eptifibatide Administration South Med J 103 6 2010 596 597
35. M.W. Tempelhof, K.H. Benzuly, D. Fintel, and M.Z. Krichavsky Eptifibatide-Induced Thrombocytopenia: with Thrombosis and Disseminated Intravascular Coagulation Immediately after Left Main Coronary Artery Percutaneous Coronary Angioplasty Tex Heart Inst J 39 1 2012 86
36. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 9063 1997 1422 1428
37. The PURSUIT Investigators Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes N Eng J Med 339 7 1998 436 443
38. F.K. Keating, H.L. Dauerman, D.A. Whitaker, B.E. Sobel, and D.J. Schneider Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin Thromb Res 118 3 2006 361 369
39. R. Cabannes, J. Lonsdorfer, J. Castaigne, A. Ondo, A. Plassard, and I. Zohoun Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises Agents Actions Suppl 15 1984 199
40. H. Chaplin Jr., N. Alkjaersig, A. Fletcher, J. Michael, and J. Joist Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises Thromb Haemost 43 3 1980 218
41. J. Greenberg, K. Ohene-Frempong, J. Halus, C. Way, and E. Schwartz Trial of low doses of aspirin as prophylaxis insickle cell disease J Pediatr 102 5 1983 781 784
42. N. Osamo, D. Photiades, and A. Famodu Therapeutic effect of aspirin in sickle cell anaemia Acta Haematol 66 2 1981 102 107
43. M. Semple, S. Al-Hasani, P. Kioy, and G. Savidge A double-blind trial of ticlopidine in sickle cell disease Thromb Haemost 51 3 1984 303
44. M. Zago, F. Costa, S. Ismael, L. Tone, and C. Bottura Treatment of sickle cell diseases with aspirin Acta Haematol 72 1 1984 61 64
45. T. Wun, D. Soulieres, A. Frelinger, L. Krishnamurti, E. Novelli, and A. Kutlar A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease J Hematol Oncol 6 1 2013 17